Imagine your liver is like a filter that can get clogged by fat. While we usually blame diet, some invisible chemicals in our environment act like glitches that speed up this clogging process. This work identifies which specific chemicals are the culprits and how they differ between men and women.
MASLD affects 25% of the population and lacks approved therapies, creating a massive economic burden. There is a critical lack of tools to identify how environmental chemicals accelerate this disease.
The project is building 2D/3D human hepatocyte models and integrative systems biology screening platforms to test chemical mixtures.
If you are a drug discovery firm dealing with the lack of approved therapies for MASH — this project developed screening platforms and mechanistic insights into EDC-induced injury that help identify new drug targets.
If you are a toxicology lab dealing with outdated chemical safety tests — this project developed 2D/3D human hepatocyte models and screening tools to assess how chemical mixtures impact liver health.
If you are a biomarker developer dealing with imprecise liver disease staging — this project developed multi-omics and steroidomic profiling data from 1,600 samples to identify markers of disease progression.
Based on available project data, no pricing or cost information for the tools is provided.
The project is building integrative systems biology and screening platforms, but based on available project data, industrial scaling capacity is not yet specified.
Based on available project data, specific IP or licensing terms for the 2D/3D hepatocyte models have not been disclosed.
The project provides an evidence base to support EU chemical safety policy and regulatory actions to protect human health from EDCs.
The project period runs from 2024-01-01 to 2028-12-31.
The consortium is heavily research-oriented, consisting of 15 partners across 10 countries. It is dominated by 7 universities and 7 research institutes, with only 1 industry partner (an SME), resulting in a low industry ratio of 7%. This suggests the project is currently focused on fundamental discovery and validation rather than immediate commercial productization.
Contact Orebro University regarding the European SLD registry data
Contact us to identify potential licensing opportunities for the 3D liver screening platforms.
